Skip to search formSkip to main contentSkip to account menu

1.2 ML temsirolimus 25 MG/ML Injection [Torisel]

Known as: Torisel 25 MG/ML in 1.2 ML Injection, TEMSIROLIMUS 25 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Torisel], Torisel KIT 
National Institutes of Health

Related topics

Related topics

8 relations
Citric Acid, AnhydrousEthanolInjectionPropylene glycol

Broader (1)

temsirolimus Injection [Torisel]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Neue S3-Leitlinie Nierenzellkarzinom bringt Ordnung in den Therapiealltag
— Die erste deutsche evidenz-und konsensbasierte S3-Leitlinie zum Nierenzellkarzinom „Diagnostik, Therapie und Nachsorge des… 
2016
2016
Renale Angiomyolipome bei tuberöser Sklerose: Everolimus reduziert das Tumorvolumen rasch
— Die erste deutsche evidenz-und konsensbasierte S3-Leitlinie zum Nierenzellkarzinom „Diagnostik, Therapie und Nachsorge des… 
2014
2014
NT 77 - 2014 NATS Temsirolimus (Torisel®) no tratamento do câncer renal
2012
2012
Medical Optimization of Torisel® (MOTOR): A Phase II Trial of Temsirolimus as Second-Line Treatment for Advanced RCC by the Italian Kidney Cancer Group (GIR)
2012
2012
Abstract LB-226: mTOR inhibition by Temsirolimus as second-line treatment for advanced RCC: The Medical optimization of Torisel® (MoTOR) phase II trial by the Italian Kidney Cancer Group (GIR)
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: The mammalian target of rapamycin… 
2011
2011
Effets secondaires cutanés du bortezomib, à propos d’un cas
2011
2011
TORISEL® (temsirolimus, Pfizer): Inhibiteur sélectif de la protéine mTOR (mammalian Target of Rapamycin)
Le temsirolimus est un inhibiteur selectif de la proteine mTOR. Sous la forme d'une solution a diluer, il est indique dans le… 
Review
2009
Review
2009
Aktuelles zur Systemtherapie des metastasierten Nierenzellkarzinoms
ZusammenfassungDie letzten 5 Jahre waren durch grundlegende Veränderungen in der Systemtherapie des metastasierten… 
2009
2009
Novel experimental targeted therapy of neuroblastoma
Neuroblastoma, a malignancy of the sympathetic nervous system, is the most common solid extracranial tumor of infancy and is… 
2008
2008
Comment gérer au mieux la toxicité des traitements antiangiogéniques
Le traitement du cancer du rein metastatique (CRM) a ete transforme par ľavenement des antiangiogeniques: sunitinib (Sutent®) et… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)